Recurrent Mild Acute Rejections and Donor-specific Antibodies as Risk Factors for Cardiac Allograft Vasculopathy in a National Pediatric Heart Transplant Cohort.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
05
07
2023
accepted:
24
07
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Immune-mediated factors such as acute cellular rejections and donor-specific antibodies (DSAs) are risk factors for cardiac allograft vasculopathy (CAV). We studied a national cohort with a unified setting and thorough protocol endomyocardial biopsy (EMB) data for an association between cellular rejections, especially when mild and recurrent, and DSAs with CAV in pediatric heart transplant (HTx) patients. This is a retrospective, national cohort study of 94 pediatric HTxs performed between 1991 and 2019 and followed until December 31, 2020. Diagnosis of CAV was based on reevaluation of angiographies. Protocol and indication EMB findings with other patient data were collected from medical records. Associations between nonimmune and immune-mediated factors and CAV were analyzed with univariable and multivariable Cox regression analyses. Angiographies performed on 76 patients revealed CAV in 23 patients (30%). Altogether 1138 EMBs (92% protocol biopsies) were performed on 78 patients (83%). During the first posttransplant year, grade 1 rejection (G1R) appeared in 45 patients (58%), and recurrent (≥2) G1R findings in 14 patients (18%). Pretransplant DSAs occurred in 13 patients (17%) and posttransplant DSAs in 37 patients (39%). In univariable analysis, pretransplant DSAs, appearance and recurrence of G1R findings, and total rejection score during the first posttransplant year, as well as recurrent G1R during follow-up, were all associated with CAV. In multivariable analysis, pretransplant DSAs and recurrent G1R during the first posttransplant year were found to be associated with CAV. Our results indicate that pretransplant DSA and recurrent G1R findings, especially during the first posttransplant year, are associated with CAV after pediatric HTx.
Sections du résumé
Background
UNASSIGNED
Immune-mediated factors such as acute cellular rejections and donor-specific antibodies (DSAs) are risk factors for cardiac allograft vasculopathy (CAV). We studied a national cohort with a unified setting and thorough protocol endomyocardial biopsy (EMB) data for an association between cellular rejections, especially when mild and recurrent, and DSAs with CAV in pediatric heart transplant (HTx) patients.
Methods
UNASSIGNED
This is a retrospective, national cohort study of 94 pediatric HTxs performed between 1991 and 2019 and followed until December 31, 2020. Diagnosis of CAV was based on reevaluation of angiographies. Protocol and indication EMB findings with other patient data were collected from medical records. Associations between nonimmune and immune-mediated factors and CAV were analyzed with univariable and multivariable Cox regression analyses.
Results
UNASSIGNED
Angiographies performed on 76 patients revealed CAV in 23 patients (30%). Altogether 1138 EMBs (92% protocol biopsies) were performed on 78 patients (83%). During the first posttransplant year, grade 1 rejection (G1R) appeared in 45 patients (58%), and recurrent (≥2) G1R findings in 14 patients (18%). Pretransplant DSAs occurred in 13 patients (17%) and posttransplant DSAs in 37 patients (39%). In univariable analysis, pretransplant DSAs, appearance and recurrence of G1R findings, and total rejection score during the first posttransplant year, as well as recurrent G1R during follow-up, were all associated with CAV. In multivariable analysis, pretransplant DSAs and recurrent G1R during the first posttransplant year were found to be associated with CAV.
Conclusions
UNASSIGNED
Our results indicate that pretransplant DSA and recurrent G1R findings, especially during the first posttransplant year, are associated with CAV after pediatric HTx.
Identifiants
pubmed: 37745950
doi: 10.1097/TXD.0000000000001534
pmc: PMC10513139
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1534Informations de copyright
Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
J Heart Lung Transplant. 2015 Oct;34(10):1310-7
pubmed: 26123951
Am J Transplant. 2018 Sep;18(9):2163-2174
pubmed: 29442424
Lancet Child Adolesc Health. 2021 May;5(5):341-349
pubmed: 33743201
Pediatr Transplant. 2022 May;26(3):e14218
pubmed: 34985793
J Am Coll Cardiol. 2001 Jan;37(1):243-50
pubmed: 11153746
Pediatr Transplant. 2013 Aug;17(5):436-40
pubmed: 23714284
Circulation. 1991 Nov;84(5 Suppl):III303-9
pubmed: 1657452
J Heart Lung Transplant. 2005 Nov;24(11):1710-20
pubmed: 16297770
J Heart Lung Transplant. 2010 Jul;29(7):717-27
pubmed: 20620917
Am J Clin Pathol. 2014 Dec;142(6):809-15
pubmed: 25389335
Circulation. 1993 Nov;88(5 Pt 2):II224-9
pubmed: 8222158
Curr Opin Organ Transplant. 2019 Jun;24(3):245-251
pubmed: 31090631
J Heart Lung Transplant. 2017 May;36(5):540-545
pubmed: 27916323
Pediatr Transplant. 2021 Nov;25(7):e14043
pubmed: 34390091
Clin Transplant. 2018 Nov;32(11):e13416
pubmed: 30276870
J Heart Lung Transplant. 2005 Aug;24(8):1039-45
pubmed: 16102439
J Heart Lung Transplant. 2005 Jun;24(6):645-51
pubmed: 15949722
Pediatr Transplant. 2011 Sep;15(6):589-93
pubmed: 21884346
Transplant Rev (Orlando). 2018 Oct;32(4):207-217
pubmed: 29804793
Transplantation. 2020 Jan;104(1):e31-e37
pubmed: 31568274
J Heart Lung Transplant. 1995 May-Jun;14(3):452-60
pubmed: 7654730
J Heart Lung Transplant. 2009 Apr;28(4):320-7
pubmed: 19332257
J Heart Lung Transplant. 2021 Oct;40(10):1050-1059
pubmed: 34420853
J Heart Lung Transplant. 2016 Jan;35(1):87-91
pubmed: 26422083
J Heart Lung Transplant. 2019 Oct;38(10):1028-1041
pubmed: 31548029
J Heart Lung Transplant. 2022 Oct;41(10):1401-1413
pubmed: 35872109
Interact Cardiovasc Thorac Surg. 2016 Jul;23(1):18-25
pubmed: 27034098
Ann Thorac Surg. 2021 Oct;112(4):1282-1289
pubmed: 33039362